Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 131

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 131
---
 on the same basis as the other participants in the bonus plan, except that the bonus amount shall be prorated based on the percentage of days Dr. Waltzman was employed relative to the total number of days in the bonus earning period.

| 90 |

Equity Compensation Plans

The following table gives information as of December 31, 2024 about shares of our common stock that may be issued upon the exercise of options under the Indaptus Therapeutics, Inc. 2021 Stock Incentive Plan (the “2021 Plan”):

| Plan Category                                              |     | Number of securities to be issued upon exercise of outstanding options, warrants and rights(1) |           |     | Weighted-average exercise price of outstanding options, warrants and rights |      |     | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) |         |
|:-----------------------------------------------------------|:----|:-----------------------------------------------------------------------------------------------|----------:|:----|:----------------------------------------------------------------------------|-----:|:----|:----------------------------------------------------------------------------------------------------------------------------------------------|--------:|
| Equity compensation plan approved by security holders(2)   |     |                                                                                                | 2,887,822 |     | $                                                                           | 8.06 |     |                                                                                                                                               | 103,608 |
| Equity compensation plans not approved by security holders |     |                                                                                                |         — |     |                                                                             |    — |     |                                                                                                                                               |       — |

(1) Represents stock options outstanding under the 2021 Plan.

(2) Our 2021 Plan has an evergreen provision that allows for an annual increase on each January 1 from January 1, 2025 and ending on and including January 1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of our shares of common stock outstanding on the final day of the immediately preceding calendar year or (B) such smaller number of shares as is determined by our Board of Directors.

Pay Versus Performance Table

The following table sets forth information concerning the compensation of our named executive officers, or NEOs, the compensation actually paid to our NEOs, as determined under SEC rules (and described below), our total shareholder return and our net loss, in each case for each of the fiscal years ended December 31, 2022, 2023 and 2024:

| (a)  | Year | (b) |         Summary 
    Compensation 
 Table Total for 
         PEO ($) |